Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp(University of Würzburg), Nicola Gökbuget(Goethe University Frankfurt), Anthony S. Stein(City of Hope), Gerhard Zugmaier(Amgen (Germany)), Susan O’Brien(The University of Texas MD Anderson Cancer Center), Ralf C. Bargou(Comprehensive Cancer Center Mainfranken), Hervé Dombret(Hôpital Saint-Louis), Adele K. Fielding(University College London), Leonard T. Heffner(Emory University), Richard A Larson(University of Illinois Chicago), Svenja Neumann(Schmerzklinik Kiel), Robin Foà(Sapienza University of Rome), Mark R. Litzow(Mayo Clinic in Arizona), Josep‐María Ribera(Josep Carreras Leukaemia Research Institute), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Gary J. Schiller(University of California, Los Angeles), Monika Brüggemann(Christian-Albrechts-Universität zu Kiel), Heinz A. Horst(Christian-Albrechts-Universität zu Kiel), Chris Holland(Amgen (United States)), Catherine Jia(Amgen (United States)), Tapan Maniar(Amgen (United States)), Birgit Huber(Amgen (Germany)), Dirk Nagorsen(Amgen (United States)), Stephen J. Forman(City of Hope), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center)
Cited by 1,252
Abstract
Related Papers
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Ethan Basch, Bryce B. Reeve, Sandra A. Mitchell et al.|JNCI Journal of the National Cancer Institute|2014|1.1k